Abstract:Objective To investigate the effect and safety of low-dose rituximab combined with cyclosporine A on CD20+ and platelet count in patients with refractory and recurrent idiopathic thrombocytopenic purpura (ITP).Methods A total of 58 patients with refractory recurrent ITP who received treatment from January 2014 to January 2016 at Zigong Forth People’s Hospital were selected as study subjects,and all the patients were divided into control group and observation group randomly ( n=29,each).The control group was treated with dexamethasone,and the observation group was treated with low dose of rituximab and cyclosporine A.The period of treatment was 3-4 months.The clinical efficacy,changes of CD20+ and platelet count of the two groups were dynamically monitored and analyzed.Results After treatment,the total effective rate of the observation group was higher than that of the control group(89.66% vs 65.52%, χ2=4.858, P<0.05).Compared with control group,the platelet count in the observation group was significantly higher and the level of CD20+ was significantly lower in the observation group ( P<0.05).Liver and kidney function injury,fever,pulmonary infection,rash and digestive tract infection adverse reactions occurred in the two groups without significant difference ( P>0.05).Conclusion Low dose rituximab combined with cyclosporine A has good clinical effect in the treatment of refractory and recurrent ITP,which could effectively improve the expression level of CD20+ and platelet count with good safety.